Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Ford, A. Marshall, J. Bridgewater, T. Janowitz, F. Coxon, J. Wadsley, W. Mansoor, D. Fyfe, S. Madhusudan, G. Middleton, D. Swinson, S. Falk, I. Chau, D. Cunningham, Paula Kareclas, N. Cook, J. Blazeby, J. Dunn (2014)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.The Lancet. Oncology, 15 1
P. Thuss-Patience, A. Kretzschmar, D. Bichev, T. Deist, A. Hinke, K. Breithaupt, Y. Doğan, B. Gebauer, G. Schumacher, P. Reichardt (2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).European journal of cancer, 47 15
D. Le, J. Bendell, E. Calvo, Joseph Kim, P. Ascierto, P. Sharma, P. Ott, P. Bono, D. Jaeger, T. Evans, F. Braud, I. Chau, O. Christensen, C. Harbison, Chen-Sheng Lin, Y. Janjigian (2016)
Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.Journal of Clinical Oncology, 34
E. Smyth, M. Verheij, W. Allum, D. Cunningham, A. Cervantes, D. Arnold (2010)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
R. Herbst, P. Baas, Dong-Wan Kim, E. Felip, J. Pérez-Gracia, Ji-Youn Han, J. Molina, Joo‐Hang Kim, C. Arvis, M. Ahn, M. Majem, M. Fidler, G. Castro, M. Garrido, G. Lubiniecki, Shentu Yue, E. Im, M. Dolled-Filhart, E. Garon (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 387
O. Hamid, C. Robert, A. Ribas, J. Wolchok, F. Hodi, R. Kefford, A. Joshua, W. Hwu, T. Gangadhar, A. Patnaik, P. Hersey, J. Weber, R. Joseph, K. Gergich, Xiaoyun Li, P. Chun, S. Ebbinghaus, S. Kang, A. Daud (2014)
Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).Journal of Clinical Oncology, 32
K. Muro, H. Chung, V. Shankaran, R. Geva, D. Catenacci, Shilpa Gupta, J. Eder, T. Golan, D. Le, B. Burtness, A. Mcree, Chia‐Chi Lin, K. Pathiraja, J. Lunceford, K. Emancipator, J. Juco, M. Koshiji, Y. Bang (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.The Lancet. Oncology, 17 6
G. Freeman, A. Long, Yoshiko Iwai, K. Bourque, T. Chernova, H. Nishimura, L. Fitz, Nelly Malenkovich, Taku Okazaki, M. Byrne, H. Horton, L. Fouser, L. Carter, V. Ling, M. Bowman, B. Carreno, M. Collins, C. Wood, T. Honjo (2000)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 192
Wagner (2010)
Chemotherapy for advanced gastric cancer.Cochrane Database Syst Rev
H. Chung, H. Arkenau, L. Wyrwicz, D. Oh, Keun-Wook Lee, J. Infante, K. Chin, A. Heydebreck, Yoon-Koo Kang, H. Safran (2016)
Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.Journal of Clinical Oncology, 34
Kang (2012)
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.J Clin Oncol, 30
Yoon-Koo Kang, T. Satoh, M. Ryu, Y. Chao, Ken Kato, H. Chung, Jen‐Shi Chen, K. Muro, W. Kang, T. Yoshikawa, S. Oh, T. Tamura, Keun-Wook Lee, N. Boku, Li‐Tzong Chen (2017)
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.Journal of Clinical Oncology, 35
J. Wolchok, A. Hoos, S. O'Day, J. Weber, O. Hamid, C. Lebbé, M. Maio, Michael Binder, O. Bohnsack, G. Nichol, R. Humphrey, Stephen Hodi (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 15
Smyth (2016)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol, 27
O. Abdel-Rahman (2016)
Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials.Critical reviews in oncology/hematology, 97
S. Goldberg, S. Gettinger, A. Mahajan, A. Chiang, R. Herbst, M. Sznol, A. Tsiouris, J. Cohen, A. Vortmeyer, Lucia Jilaveanu, James Yu, U. Hegde, Stephanie Speaker, Matthew Madura, A. Ralabate, A. Rivera, E. Rowen, H. Gerrish, Xiaopan Yao, V. Chiang, H. Kluger (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.The Lancet. Oncology, 17 7
E. Plimack, J. Bellmunt, Shilpa Gupta, R. Berger, L. Chow, J. Juco, J. Lunceford, S. Saraf, R. Perini, P. O’Donnell (2017)
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.The Lancet. Oncology, 18 2
Therasse (2000)
New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst, 92
Cancer Program (2003)
Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
T. Kojima, H. Hara, K. Yamaguchi, S. Hironaka, S. Iwasa, Ken Kato, T. Tsushima, H. Yasui, T. Ura, K. Muro, T. Satoh, Y. Doki, A. Ohtsu, Y. Hamamoto, Y. Kitagawa (2016)
Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.Journal of Clinical Oncology, 34
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, D. Forman (2011)
Global cancer statisticsCA: A Cancer Journal for Clinicians, 61
T. Seiwert, B. Burtness, R. Mehra, J. Weiss, R. Berger, J. Eder, K. Heath, T. Mcclanahan, J. Lunceford, C. Gause, Jonathan Cheng, L. Chow (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.The Lancet. Oncology, 17 7
Jemal (2011)
Global cancer statistics.CA Cancer J Clin, 61
R. Nanda, L. Chow, C. Dees, R. Berger, Shilpa Gupta, R. Geva, L. Pusztai, K. Pathiraja, G. Aktan, Jonathan Cheng, V. Karantza, L. Buisseret (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 21
M. Ayers, J. Lunceford, M. Nebozhyn, E. Murphy, A. Loboda, D. Kaufman, Andrew Albright, Jonathan Cheng, S. Kang, V. Shankaran, S. Piha-Paul, J. Yearley, T. Seiwert, A. Ribas, T. Mcclanahan (2017)
IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade
D. Pfister, K. Ang, D. Brizel (2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Yoon-Koo Kang, N. Boku, T. Satoh, M. Ryu, Y. Chao, Ken Kato, H. Chung, Jen‐Shi Chen, K. Muro, W. Kang, K. Yeh, T. Yoshikawa, S. Oh, L. Bai, T. Tamura, Keun-Wook Lee, Y. Hamamoto, Jong Kim, K. Chin, D. Oh, K. Minashi, J. Cho, M. Tsuda, Li‐Tzong Chen (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 390
C. Clopper, E. Pearson (1934)
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 26
F. Duffaud, P. Therasse (2000)
[New guidelines to evaluate the response to treatment in solid tumors].Bulletin du cancer, 87 12
J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. Parkin, D. Forman, F. Bray (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 136
N. Segal, Omid Hamid, W. Hwu, C. Massard, Marcus Butler, S. Antonia, A. Blake-Haskins, P. Robbins, Xia Li, Jim Vasselli, Samir Khleif (2014)
1058PDA PHASE I MULTI-ARM DOSE-EXPANSION STUDY OF THE ANTI-PROGRAMMED CELL DEATH-LIGAND-1 (PD-L1) ANTIBODY MEDI4736: PRELIMINARY DATA.Annals of oncology : official journal of the European Society for Medical Oncology, 25 suppl_4
W. Chan, K. Yuen, S. Siu, K. Lam, D. Kwong (2017)
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis.Critical reviews in oncology/hematology, 116
S. Derks, S. Derks, X. Liao, A. Chiaravalli, Xinsen Xu, M. Camargo, E. Solcia, F. Sessa, T. Fleitas, G. Freeman, S. Rodig, C. Rabkin, A. Bass (2016)
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancersOncotarget, 7
F. Lordick, K. Shitara, Y. Janjigian (2017)
New agents on the horizon in gastric cancerAnnals of Oncology, 28
S. Hironaka, S. Ueda, H. Yasui, T. Nishina, M. Tsuda, T. Tsumura, N. Sugimoto, H. Shimodaira, S. Tokunaga, T. Moriwaki, T. Esaki, M. Nagase, K. Fujitani, K. Yamaguchi, T. Ura, Y. Hamamoto, S. Morita, I. Okamoto, N. Boku, I. Hyodo (2013)
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 35
A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid, C. Robert, F. Hodi, J. Schachter, A. Pavlick, Karl Lewis, L. Cranmer, Christian Blank, S. O'Day, P. Ascierto, April Salama, K. Margolin, C. Loquai, Thomas Eigentler, T. Gangadhar, M. Carlino, S. Agarwala, S. Moschos, J. Sosman, S. Goldinger, R. Shapira-Frommer, R. Gonzalez, J. Kirkwood, J. Wolchok, A. Eggermont, Xiaoyun Li, W. Zhou, Adriane Zernhelt, Joy Lis, S. Ebbinghaus, S. Kang, A. Daud (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.The Lancet. Oncology, 16 8
C. Fuchs, J. Tomasek, Cho Yong, Filip Dumitru, R. Passalacqua, C. Goswami, H. Safran, L. Santos, G. Aprile, D. Ferry, B. Melichar, M. Tehfé, E. Topuzov, J. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A. Liepa, L. Gao, J. Schwartz, J. Tabernero (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialThe Lancet, 383
S. Al-Batran, E. Jäger, M. Scholz (2007)
Chemotherapy for advanced gastric cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 6
A. Bass, V. Thorsson, I. Shmulevich, Sheila Reynolds, Michael Miller, Brady Bernard, T. Hinoue, P. Laird, C. Curtis, Hui Shen, D. Weisenberger, N. Schultz, R. Shen, Nils Weinhold, D. Kelsen, R. Bowlby, Andy Chu, K. Kasaian, A. Mungall, A. Robertson, Payal Sipahimalani, A. Cherniack, G. Getz, Yingchun Liu, M. Noble, C. Pedamallu, C. Sougnez, A. Taylor-Weiner, R. Akbani, Ju-Seog Lee, Wenbin Liu, G. Mills, Da Yang, Wei Zhang, A. Pantazi, Michael Parfenov, M. Gulley, M. Piazuelo, B. Schneider, Jihun Kim, A. Boussioutas, Margi Sheth, John Demchok, C. Rabkin, J. Willis, S. Ng, Katherine Garman, D. Beer, A. Pennathur, Benjamin Raphael, Hsin-Ta Wu, R. Odze, H. Kim, Jay Bowen, K. Leraas, T. Lichtenberg, Stephanie Weaver, M. McLellan, M. Wiznerowicz, R. Sakai, M. Lawrence, K. Cibulskis, Lee Lichtenstein, Sheila Fisher, S. Gabriel, E. Lander, L. Ding, B. Niu, Adrian Ally, M. Balasundaram, I. Birol, Denise Brooks, Y. Butterfield, R. Carlsen, Justin Chu, E. Chuah, Hye-Jung Chun, A. Clarke, Noreen Dhalla, R. Guin, R. Holt, Steven Jones, Darlene Lee, Haiyan Li, E. Lim, Yussanne Ma, M. Marra, Michael Mayo, Richard Moore, K. Mungall, K. Nip, J. Schein, Angela Tam, N. Thiessen, R. Beroukhim, S. Carter, A. Cherniack, Juok Cho, D. Dicara, S. Frazer, N. Gehlenborg, David Heiman, Joonil Jung, Jaegil Kim, Pei Lin, M. Meyerson, A. Ojesina, C. Pedamallu, G. Saksena, S. Schumacher, P. Stojanov, B. Tabak, Douglas Voet, Mara Rosenberg, Travis Zack, Hailei Zhang, L. Zou, A. Protopopov, Netty Santoso, Semin Lee, Jianhua Zhang, Harshad Mahadeshwar, Jiabin Tang, X. Ren, S. Seth, Lixing Yang, A. Xu, Xingzhi Song, Ruibin Xi, C. Bristow, Angela Hadjipanayis, J. Seidman, L. Chin, P. Park, R. Kucherlapati, Shiyun Ling, A. Rao, J. Weinstein, Sang-Bae Kim, Ju-Seog Lee, Yiling Lu, G. Mills, M. Bootwalla, Phillip Lai, T. Triche, D. Berg, S. Baylin, J. Herman, Bradley Murray, B. Askoy, G. Ciriello, Gideon Dresdner, Jianjiong Gao, Benjamin Gross, A. Jacobsen, William Lee, Ricardo Ramirez, C. Sander, Y. Şenbabaoğlu, Rileen Sinha, S. Sumer, Yichao Sun, V. Thorsson, L. Iype, R. Kramer, R. Kreisberg, Hector Rovira, Natalie Tasman, S. Ng, D. Haussler, Josh Stuart, R. Verhaak, Mark Leiserson, B. Taylor, Aaron Black, Julie Carney, J. Gastier-Foster, Carmen Helsel, Cynthia McAllister, N. Ramirez, Teresa Tabler, L. Wise, E. Zmuda, R. Penny, D. Crain, J. Gardner, Kevin Lau, Erin Curely, D. Mallery, S. Morris, J. Paulauskis, T. Shelton, C. Shelton, M. Sherman, C. Benz, Jaehyuk Lee, K. Fedosenko, G. Manikhas, O. Potapova, Olga Voronina, S. Belyaev, Oleg Dolzhansky, W. Rathmell, Jakub Brzeziński, Matthew Ibbs, Konstanty Korski, W. Kycler, Radoslaw ŁaŸniak, E. Leporowska, A. Mackiewicz, D. Murawa, P. Murawa, A. Spychała, W. Suchorska, Honorata Tatka, M. Teresiak, R. Abdel-Misih, Joseph Bennett, Jennifer Brown, M. Iacocca, B. Rabeno, S. Kwon, A. Kemkes, Erin Curley, I. Alexopoulou, J. Engel, J. Bartlett, Monique Albert, D. Park, R. Dhir, J. Luketich, R. Landreneau, Y. Janjigian, E. Cho, M. Ladanyi, Laura Tang, S. McCall, Y. Park, J. Cheong, J. Ajani, M. Camargo, S. Alonso, Brenda Ayala, M. Jensen, T. Pihl, R. Raman, Jessica Walton, Yunhu Wan, G. Eley, Kenna Shaw, R. Tarnuzzer, Zhining Wang, Liming Yang, J. Zenklusen, Tanja Davidsen, C. Hutter, H. Sofia, R. Burton, Sudha Chudamani, Jia Liu (2014)
Comprehensive molecular characterization of gastric adenocarcinomaNature, 513
B. Wallden, I. Pekker, S. Popa, N. Dowidar, A. Sullivan, T. Hood, P. Danaher, Afshin Mashadi-Hossein, J. Lunceford, M. Marton, Ken Chang, S. Ferree, J. Storhoff (2016)
Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System.Journal of Clinical Oncology, 34
Lindsey Torre, F. Bray, R. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal (2015)
Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 65
H. Wilke, K. Muro, E. Cutsem, S. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, Tae-You Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J. Schwartz, A. Ohtsu (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.The Lancet. Oncology, 15 11
J. Thigpen (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care AloneYearbook of Oncology, 2012
Key PointsQuestionIs pembrolizumab monotherapy safe and effective in patients with previously treated gastric and gastroesophageal junction cancer? FindingsAmong 259 patients with previously treated gastric and gastroesophageal junction cancer enrolled in the phase 2 KEYNOTE-059 single-arm, multicohort trial, pembrolizumab demonstrated manageable safety. The objective response rate was 11.6% (30 of 259 patients), and complete responses were observed in 2.3% of patients (6 of 259); the median (range) response duration was 8.4 (1.6 + to 17.3+) months (+ indicates that patients had no progressive disease at their last assessment). MeaningThese results support further development of pembrolizumab for patients with gastric and gastroesophageal junction cancer who have received 2 or more lines of therapy.
JAMA Oncology – American Medical Association
Published: May 15, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.